Subject
Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health
Reference33 articles.
1. Cystic Fibrosis Foundation Patient Registry, Annual Data Report 2020, in Bethesda, Maryland ©2021 Cystic Fibrosis Foundation 2020.
2. Disease-modifying drug therapy in cystic fibrosis;Harman;Paediatr Respir Rev,2018
3. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del);Southern;Cochrane Database Syst Rev,2020
4. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: interim Results of an Open-Label Phase 3 Clinical Trial;Griese;Am J Respir Crit Care Med,2021
5. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman;Lancet,2019
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献